- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02234986
A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
September 4, 2018 updated by: CASI Pharmaceuticals, Inc.
A Phase 2, Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma (FLC)
The purpose of the study is to determine whether once-daily dosing with ENMD-2076 will be a safe and effective treatment in patients with FLC.
Safety will be measured by looking at the adverse events that may happen and the efficacy will look at the progression of the disease over time.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Primary Objective:
• To determine the 6-month progression free survival (PFS6) rate when patients with advanced fibrolamellar carcinoma (FLC) are treated with daily oral ENMD 2076
Secondary Objectives:
- To evaluate the overall response rate using RECIST v 1.1 criteria when patients with FLC are treated with daily oral ENMD 2076.
- To evaluate the median Progression Free Survival (PFS), Time to Progression (TTP), and Overall Survival (OS).
- To determine the safety of ENMD-2076 as defined by the frequency and severity of adverse events when patients with FLC are treated with daily oral ENMD-2076
Study Type
Interventional
Enrollment (Actual)
37
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94158
- CASI Site 03
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- CASI Site 04
-
-
Massachusetts
-
Boston, Massachusetts, United States, 01003
- CASI Site 02
-
-
New York
-
New York, New York, United States, 10065
- Casi Site 01
-
-
Texas
-
Dallas, Texas, United States, 75231
- CASI Site 05
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 99 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically or cytologically confirmed advanced fibrolamellar carcinoma (FLC).
- All forms of prior local therapy are allowed as long as patients have either a target lesion, which has not been treated with local therapy and/or the target lesion(s) within the field of the local-regional therapy has shown an increase of ≥ 20% in size. Local-regional therapy must be completed at least 4 weeks prior to the baseline CT scan. Local therapies including chemoembolization do not count as prior systemic therapy.
- Are at least 4 weeks from major surgery and recovered.
- At least one measureable lesion by RECIST 1.1.
- Male or non-pregnant, non-breastfeeding female at least 18 years of age. Patients aged at 12~18 years may be recruited but only at the site principle investigator's request and subject to IRB approval.
- Has a pre-study echocardiogram or multi-gated acquisition (MUGA) scan with an actual left ventricular ejection fraction of greater than or equal to the institutional lower limit of normal within one month of initiating therapy.
Have clinically acceptable laboratory screening results within certain limits specified below:
- AST and ALT ≤ 5 times upper limit of normal (ULN)
- Total bilirubin ≤ 3.0 x ULN
- Creatinine ≤ 1.5 x ULN or Cr Cl > 60 cc/min
- Absolute neutrophil count ≥ 1500 cells/mm3
- Platelets ≥ 50,000/mm3
- Have an ECOG performance status of 0-2 for ≥ 16 years of age and a Lansky performance status of 70-100 for < 16 years of age
- Women and men of child producing potential must agree to use effective contraceptive methods prior to study entry, during study participation, and for at least 30 days after the last administration of study medication. A serum pregnancy test within 72 hours prior to the initiation of therapy will be required for women of childbearing potential.
- Have the ability to understand the requirements of the study, provide written informed consent, which includes authorization for release of protected health information, abide by the study restrictions, and agree to return for the required assessments.
Exclusion Criteria:
- Have active, acute, or chronic clinically significant infections or bleeding within the last 6 months or previous thromboembolic or hemorrhagic events during anti angiogenic therapy.
- Have uncontrolled hypertension (systolic blood pressure greater than 150 or diastolic blood pressure greater than 100) or history of congestive heart failure (AHA Grade 2 or higher).
- Have active angina pectoris, stroke or recent myocardial infarction (within 6 months).
- Have uncontrolled chronic atrial fibrillation.
- Have chronic atrial fibrillation or QTc interval corrected for heart rate of greater than 470 msec in adults and 450 msec in pediatrics (< 18 years).
- Have additional uncontrolled serious medical or psychiatric illness that in the point of view of the investigator can render the patient unable to receive therapy or make it unsafe to receive therapy.
- Require treatment with any of the exclusionary medications listed in Appendix D.
- Known untreated or unstable CNS metastatic disease.
- Have persistent 2+ protein by urinalysis (patients with 2+ proteinuria that have a spot protein:creatinine ratio of less than 0.3 may be enrolled) or a history of nephrotic syndrome.
- Subjects with history of another primary cancer, with the exception of: a) curatively resected non-melanoma skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid tumor with no known active disease present in the opinion of the investigator will not affect patient outcome in the setting of current FLC diagnosis.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ENMD-2076
ENMD-2076, oral capsule Once daily dose 250 mg/day
|
250 mg oral dose, QD for 28 day cycles
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate
Time Frame: 6 months
|
6-month overall response rate (ORR rate) using RECIST v1.1 criteria
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival (PFS6) rate
Time Frame: 6 months
|
Overall response rate using RECIST v 1.1 criteria
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency and severity of adverse events
Time Frame: 6 months
|
Frequency and severity of adverse events
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Ken Ren, PhD, CASI Pharmaceuticals, Inc.
- Study Chair: Ghassan Abou-Alfa, MD, MSKCC
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2015
Primary Completion (ACTUAL)
June 30, 2018
Study Completion (ACTUAL)
June 30, 2018
Study Registration Dates
First Submitted
September 5, 2014
First Submitted That Met QC Criteria
September 5, 2014
First Posted (ESTIMATE)
September 9, 2014
Study Record Updates
Last Update Posted (ACTUAL)
September 6, 2018
Last Update Submitted That Met QC Criteria
September 4, 2018
Last Verified
September 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2076-CL-006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Adult Hepatocellular Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Advanced Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma | BCLC Stage B Adult Hepatocellular Carcinoma | BCLC Stage C Adult Hepatocellular CarcinomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Adult Hepatocellular Carcinoma | BCLC Stage B Adult Hepatocellular Carcinoma | BCLC Stage C Adult Hepatocellular Carcinoma | BCLC Stage D Adult Hepatocellular Carcinoma | Localized Resectable Adult Liver... and other conditionsUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular CarcinomaUnited States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
AstraZenecaIonis Pharmaceuticals, Inc.CompletedAdvanced Adult Hepatocellular Carcinoma | Hepatocellular Carcinoma MetastaticKorea, Republic of, Taiwan, Hong Kong, Japan
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer Network; AVEO...CompletedAdvanced Adult Hepatocellular Carcinoma | Non-Resectable Hepatocellular CarcinomaUnited States
-
Shenzhen SiBiono GeneTech Co.,LtdUnknownAdvanced Adult Hepatocellular CarcinomaChina
-
Acceleron Pharma Inc. (a wholly owned subsidiary...CompletedAdvanced Adult Hepatocellular CarcinomaUnited States
Clinical Trials on ENMD-2076
-
University Health Network, TorontoCompletedSoft Tissue Sarcoma | Metastatic | AdvancedCanada
-
University Health Network, TorontoCompleted
-
CASI Pharmaceuticals, Inc.University of Colorado, Denver; Indiana University Melvin and Bren Simon Cancer...CompletedTriple Negative Breast CancerUnited States, China
-
CASI Pharmaceuticals, Inc.Completed
-
CASI Pharmaceuticals, Inc.CompletedOvarian Cancer | Peritoneal Cancer | Fallopian CancerUnited States, Canada
-
CASI Pharmaceuticals, Inc.CompletedRelapsed or Refractory Hematological MalignanciesCanada
-
CASI Pharmaceuticals, Inc.CompletedAdvanced CancerUnited States